Compare Johnson & Johnson (JNJ) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Verisign, Inc. — how do they compare? Johnson & Johnson trades at $249.3 (market cap $598.96B), while Verisign, Inc. trades at $266.32 (market cap $25.26B). The key difference: Johnson & Johnson is far larger — about 23.7× Verisign, Inc.'s market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | VRSN | |
|---|---|---|
Market Cap | $598.96B | $25.26B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $310.00 |
52-Week Low | $164.36 | $211.49 |
Enterprise Value | $631.90B | $26.50B |
Dividend Yield | 2.15% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
VeriSign (VRSN) trades at $277.60, down slightly by 0.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with EPS of $2.34 beating estimates, driven by 6.6% revenue growth. Analyst consensus is a Buy with a $325.25 price target, reflecting confidence in its domain registry monopoly and robust margins.
Outlook remains positive due to predictable revenue streams from .com and .net domains, though risks include AI disruption and contract renewals. Valuation multiples like P/E of 30.68 appear elevated, requiring sustained growth to justify. Investors should weigh high margins against debt levels and competitive threats for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
